---
layout: post
title: "COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities"
date: 2026-02-05 18:35:31 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-02466
original_published: 2023-02-06 00:00:00 +0000
significance: 8.00
---

# COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 06, 2023 00:00 UTC
**Document Number:** 2023-02466

## Summary

Following receipt on December 16, 2022, of a request from the U.S. Trade Representative (USTR), under the Tariff Act of 1930, the U.S. International Trade Commission (Commission) instituted Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities. The USTR requested that the Commission conduct an investigation and prepare a report that analyzes the universe of existing COVID-19 diagnostics and therapeutics in relation to the World Trade Organization (WTO) Agreement on Trade- Related Aspects of Intellectual Property Rights (TRIPS Agreement)-- including the range of definitions for diagnostics and therapeutics; diagnostics and therapeutics covered by patents and those in development; an overview of production, distribution, and demand; information on market segmentation of global demand and consumption; and other information relevant to the discussion of TRIPS Agreement flexibilities.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/06/2023-02466/covid-19-diagnostics-and-therapeutics-supply-demand-and-trips-agreement-flexibilities)
- API: https://www.federalregister.gov/api/v1/documents/2023-02466

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
